DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for autonomic nervous system neoplasm — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutonomic nervous system neoplasm maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autonomic nervous system neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neurofibromin 1 (NF1) — NF1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7PGU · 3.3 Å · ligand (1S)-2-{[(2-AMINOETHOXY)(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL STEARATE (PEV). Experimental structure, not a prediction.
What the evidence adds up to
The 2015 review summarises evidence that autonomic nerves, together with neurotrophic growth factors and axon guidance cues, help create a microenvironment that promotes tumour formation and metastasis. No patient data, survival figures, or response rates are reported; the paper is a review of preclinical and mechanistic studies, not a clinical trial.
A 1996 paper describes paraneoplastic neurologic syndromes as degenerative conditions of the central or peripheral nervous system that arise alongside a systemic neoplasm without direct tumour invasion. The review notes increasing evidence that autoimmune processes triggered by the underlying cancer are central to the pathophysiology, supported by reports of autoantibodies that react with both neural tissue and the tumour. The paper does not report any therapeutic intervention or outcome data.
A 2000 Spanish-language review examines infectious and metabolic nervous system complications in patients with systemic cancer. It states that neurological infections are rare (0.02%–1%), with the most common underlying neoplasms being lymphomas, particularly Hodgkin type and lymphosarcomas. Frequent pathogens include herpes virus, Listeria monocytogenes, and fungi (Aspergillus, Candida, Cryptococcus). Cerebral abscesses, though rarer, are caused by gram-negative bacteria, fungi, and toxoplasmosis. The review notes a recent increase in diagnosed progressive multifocal leukoencephalopathy due to PCR detection of JC virus DNA. Metabolic complications are attributed to hormone overproduction, electrolyte disturbances, and vitamin deficits, typically causing confusion. No treatment outcomes or survival data are given.
What is still missing: no clinical trial has tested whether modulating autonomic nervous system activity alters tumour progression or survival in patients with autonomic nervous system neoplasms. There are no prospective studies linking paraneoplastic autoantibodies to a specific therapeutic strategy. No randomised data exist to guide empirical treatment of neurological infections in this population, and no validated stratification method identifies which patients might benefit from nerve-targeted interventions. Funding for a dedicated clinical trial and a clear biomarker for patient selection remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Role of the autonomic nervous system in tumorigenesis and metastasis
AbstractConvergence of multiple stromal cell types is required to develop a tumorigenic niche that nurtures the initial development of cancer and its dissemination. Although the immune and vascular systems have been shown to have strong influences on cancer, a growing body of evidence points to a role of the nervous system in promoting cancer development. This review discusses past and current research that shows the intriguing role of autonomic nerves, aided by neurotrophic growth factors and axon cues, in creating a favorable environment for the promotion of tumor formation and metastasis.
Internal Medicine · 1996 · 4 citations · open access
Paraneoplastic Neurologic Syndromes.
AbstractParaneoplastic neurologic syndromes are degenerative diseases of the central or peripheral nervous system that develop in association with a systemic neoplasm without a direct invasion by tumor. The pathogenesis of this disorder has been hypothesized in the past, and now there is increasing evidence that autoimmune processes triggered by the underlying neoplasm play a major role in the pathophysiology, as documented by many reports of identification of autoantibodies that react with both the target neural tissue and the underlying neoplasm, as evidenced by the extensive application of molecular biology techniques. The presence of antibodies in serum or CSF of some patients with this disorder now accurately identifies the subgroup of the disorders related to specific neoplasms. The trend of recent studies on the pathogenesis of this disease may in the future lead to a new era to clarify the pathogenesis.
Complicaciones infecciosas y metabólicas del sistema nervioso debidas a cáncer sistémico
AbstractOBJECTIVE: To review the incidence and causes of the infections and metabolic diseases of the nervous system in patients with systemic neoplasias. DEVELOPMENT: Patients with immunodeficiency, particularly those with hematological neoplasias and persons treated with immunosuppressive drugs have a considerable tendency to infection due to opportunist germs. Infections of the nervous system are relatively rare (0.02%-1%) and the commonest neoplasms are lymphomas, especially those of Hodgkin type and lymphosarcomas. The most frequent infections are caused by the herpes virus, meningitis due to Listeria monocytogenes and the meningitis due to fungi (Aspergillus, Candida and Cryptococcus). Cerebral abscesses, although rarer, are relatively common and are caused by gram negative bacteria, fungi and toxoplasmosis. In recent years there has been a notable increase in the number of patients diagnosed as having progressive multifocal leukoencephalopathy due to the possibility of carrying out studies to detect the DNA of the JC virus by polymerase chain reaction techniques. Empirical treatment of patients with neurological infections and systemic cancer should be started following the guidelines for immunodepressed patients. The metabolic complications of these patients are mainly due to hormone overproduction, hydroelectrolytic changes and vitamin deficits, which in general cause alterations of mental function of the confusion state type. CONCLUSION: In all patients with an infection or metabolic complication involving the nervous system, the presence of a systemic neoplasm makes it necessary to vary both the diagnostic approach and the empirical therapeutic measures taken.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
